{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:04:27Z","timestamp":1784948667482,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T00:00:00Z","timestamp":1563667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec><jats:title>Study Objective<\/jats:title><jats:p>Ceftarolinefosamil is a cephalosporin with broad clinical utility; however, limited data suggest that prolonged ceftaroline exposure may be associated with neutropenia. The objective was to determine drug and patient factors associated with neutropenia in patients receiving ceftaroline or ceftriaxone for deep\u2010seated infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective, ratio\u2010matched cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Four acute\u2010care hospitals within an urban health care system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>A total of 176 hospitalized adults who received definitive ceftaroline (44 patients) or ceftriaxone (132 patients) therapy for at least 7\u00a0days between January 2013 and April 2017 for any of the following indications: bone and joint infections (<jats:styled-content style=\"fixed-case\">BJI<\/jats:styled-content>), infective endocarditis (<jats:styled-content style=\"fixed-case\">IE<\/jats:styled-content>), or bloodstream infections (<jats:styled-content style=\"fixed-case\">BSI<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>The primary outcome was development of neutropenia while receiving cephalosporin therapy, defined as an absolute neutrophil count (<jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content>)\u00a0&lt;1500\u00a0cells\/mm<jats:sup>3<\/jats:sup>. Neutropenia severity and patient characteristics were described and compared between the ceftaroline and ceftriaxone groups. The median (interquartile range [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>]) antibiotic prescription duration was 41 (29\u201344) days for the ceftaroline group and 40 (28\u201344) days for the ceftriaxone group (p=0.9). Cephalosporin indications were 112 (64%) <jats:styled-content style=\"fixed-case\">BJI<\/jats:styled-content>, 27 (15%) <jats:styled-content style=\"fixed-case\">BSI<\/jats:styled-content>, 16 (9%) <jats:styled-content style=\"fixed-case\">IE<\/jats:styled-content>, and 21 (12%) multiple infections; ceftaroline was more commonly used in <jats:styled-content style=\"fixed-case\">BJI<\/jats:styled-content> (p=0.03), and ceftriaxone was more commonly used in <jats:styled-content style=\"fixed-case\">IE<\/jats:styled-content> (p=0.01). Neutropenia developed in 16 (9%) patients: 8 (18%) in the ceftaroline group and 8 (6%) in the ceftriaxone group (p=0.03). Median (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>) onset to neutropenia was 22 (15\u201328) days, and median (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>) change in <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content> was 2.86 (1.50\u20134.08)\u00a0cells\/mm<jats:sup>3<\/jats:sup>; most cases of neutropenia were mild (12 patients [75%]). The median (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>) time to mild or moderate\u2010severe neutropenia was not significantly different (p=0.68): 22 (14\u201328) and 22 (21\u201336) days, respectively. Treatment was discontinued in 4 (25%) patients due to neutropenia. Ceftaroline use was independently associated with neutropenia (adjusted odds ratio 3.2, 95% confidence interval 1.2\u201310.5) after adjusting for lower body mass index strata (18.5\u201325\u00a0kg\/m<jats:sup>2<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Prolonged ceftaroline use was an independent risk factor for developing mild neutropenia. Clinicians should be cognizant of <jats:styled-content style=\"fixed-case\">ANC<\/jats:styled-content> monitoring in scenarios where prolonged ceftaroline courses are prescribed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2301","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T01:59:45Z","timestamp":1561946385000},"page":"809-815","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Neutropenia Associated with Ceftaroline or Ceftriaxone in Patients Receiving at Least 7 Days of Therapy for Severe Infections"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5211","authenticated-orcid":false,"given":"Michael P.","family":"Veve","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"},{"name":"Department of Pharmacy Services Henry Ford Hospital Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Stuart","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-9486","authenticated-orcid":false,"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan"},{"name":"Department of Pharmacy Services Henry Ford Hospital Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,21]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Product Information: TEFLARO(R) intravenous injection powder ceftarolinefosamil intravenous injection powder. Forest Pharmaceuticals (per FDA) Parsippany NJ;2015."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02371-13"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01471-15"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12062"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130474"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1596"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1435"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw062"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017735629"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx452"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.187"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.38"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00009"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1376645"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3597(06)80053-0"},{"issue":"4","key":"e_1_2_6_18_1","first-page":"iv41","article-title":"CANVAS 1: the first Phase III, randomized, double\u2010blind study evaluating ceftarolinefosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey GR","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"e_1_2_6_19_1","first-page":"iv53","article-title":"CANVAS 2: the second Phase III, randomized, double\u2010blind study evaluating ceftarolinefosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox MH","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.1.90"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00117853"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.11.1657"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00117857"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730040-00002"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01595-08"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2015-0008"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:14:25Z","timestamp":1761052465000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,21]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/phar.2301"],"URL":"https:\/\/doi.org\/10.1002\/phar.2301","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,21]]},"assertion":[{"value":"2019-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}